Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Treatment
Share your love
Associations between androgen exposure, PCOS, and transmasculine individuals with central serous chorioretinopathy
Danny A. Mammo, MD, a vitreoretinal surgeon and uveitis specialist at the Cole Eye Institute at Cleveland Clinic, presented research on the association between androgen exposure and central serous chorioretinopathy (CSCR) at the 2025 scientific meeting of the American Society…
The risk of sight-threatening diabetic retinopathy with GLP-1 RA use
Andy J. Barkmeier, MD, an associate professor of ophthalmology and vitreoretinal surgery at Mayo Clinic in Rochester, Minnesota, presented findings on GLP-1 medications and their relationship to diabetic retinopathy complications at the 2025 ASRS meeting in Long Beach, California. He…
VivaVision Biotech appoints Quan Dong Nguyen to its scientific advisory board
(Image credit: AdobeStock) VivaVision Biotech Co., Ltd., appointed Quan Dong Nguyen, MD, MSc, FAAO, FARVO, FASRS, to its scientific advisory board. Nguyen is a professor of ophthalmology at the Byers Eye Institute, Stanford University School of Medicine. He is also…
The emerging era of presbyopia-correcting eye drops: What’s next?
(Image Credit: AdobeStock/taffpixture) Since 2021, only 1 prescription eye drop for the correction of presbyopia, pilocarpine HCI ophthalmic solution 1.25% (Vuity; AbbVie), has been available, with additional options expected soon. In early 2025, a second eye drop, pilocarpine HCI ophthalmic…
UK MHRA approves phase 2a study for ANXV for diabetic retinopathy
(Image credit: AdobeStock/Janis Smits) UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved the start of a clinical Proof of Concept phase 2a study with the drug candidate ANXV in the eye disease diabetic retinopathy (DR). Patients with newly…
FDA clears IND for Opus Genetics’ OPGx-BEST1 gene therapy for inherited retinal disease
(Image Credit: AdobeStock/Corona Borealis) The US Food and Drug Administration (FDA) has accepted Opus Genetics’ Investigational New Drug (IND) application for OPGx-BEST1, a gene therapy for the treatment of bestrophin-1 (BEST1)-related inherited retinal disease (IRD). Best disease, or vitelliform macular…
Study establishes reference data set for geographic atrophy lesion progression
(Image Credit: AdobeStock/tadamichi) The lesion characteristics of patients with geographic atrophy (GA) were found to affect the lesion growth rate, with fovea-sparing, multifocal, and bilateral lesions having the fastest growth rates in a study published in Translational Vision Science &…
An eye on how patients perceive their retinal diseases
(Image credit: ©De Visu/AdobeStock) A recent study identified a large disconnect between patients with neovascular age-related macular degeneration (AMD) and diabetic macular edema (DME) who are treated with intravitreal injections. The survey results highlighted the significant treatment burden experienced by…
First time results of VOY-101 for geographic atrophy
Omer Trivizki, MD, MBA, at the 2025 ASRS meeting Omer Trivizki, MD, MBA, Deputy Chair working in Tel Aviv Medical Center presented, “First time results of VOY-101, a novel, complement-modulating gene therapy for geographic atrophy.” This presentation was given at…
First patients dosed in JC02-88 study
(Image credit: ©Alernon77/AdobeStock) jCyte recently announced the dosing of the first patients enrolled in the JC02-88 study for the evaluation of famzeretcel (jCell; jCyte) for the treatment of retinitis pigmentosa (RP).1 Famzeretcel consists of allogeneic retinal progenitor cells (RPCs) administered…